How can I safely taper trazodone 150 mg and transition to suvorexant (Belsomra)?

How to Wean from Trazodone 150 mg to Belsomra

Discontinue trazodone gradually over 2-4 weeks using a slow taper (reducing by 25-50 mg every 3-7 days), then initiate Belsomra 10 mg after a brief washout period of 2-3 days, rather than attempting a direct cross-taper. This approach minimizes withdrawal symptoms from trazodone while avoiding oversedation from combining medications.

Rationale for This Approach

The evidence strongly supports discontinuing trazodone rather than continuing it. Both the American Academy of Sleep Medicine 1 and the VA/DoD guidelines 2 explicitly recommend against using trazodone for chronic insomnia treatment. The evidence shows trazodone provides minimal objective sleep benefit (only 8-10 minutes improvement in sleep parameters) with no improvement in subjective sleep quality compared to placebo 1. Meanwhile, suvorexant (Belsomra) receives a positive recommendation for sleep maintenance insomnia with demonstrated efficacy 1.

Step-by-Step Transition Protocol

Phase 1: Taper Trazodone (2-4 weeks)

Week 1-2:

• Reduce from 150 mg to 100 mg nightly
• Monitor for withdrawal symptoms: anxiety, agitation, insomnia rebound, dizziness, or flu-like symptoms 3
• Trazodone has a short half-life, making withdrawal symptoms more likely if tapered too quickly 3

Week 2-3:

• Reduce from 100 mg to 50 mg nightly
• Continue monitoring for withdrawal symptoms

Week 3-4:

• Reduce from 50 mg to 25 mg nightly for 3-4 days
• Then discontinue completely

Critical consideration: If withdrawal symptoms emerge at any step, hold at that dose for an additional 3-7 days before proceeding 4, 5. Research specifically warns that trazodone "should be tapered off at a very slow rate" due to serotonergic effects and noradrenergic rebound 3.

Phase 2: Washout Period (2-3 days)

• Allow 2-3 days after the last trazodone dose before starting Belsomra
• This brief washout minimizes risk of oversedation from drug overlap
• Research shows that adding suvorexant to existing sedative-hypnotics significantly increases oversedation risk (odds ratio 2.7) compared to switching 6

Phase 3: Initiate Belsomra

Starting dose: 10 mg taken within 30 minutes of bedtime 7

• Ensure at least 7 hours remain before planned awakening 7
• Take on empty stomach or light meal (food delays onset) 7
• Do not combine with alcohol 7

Dose adjustment if needed:

• If 10 mg is well-tolerated but ineffective after 1-2 weeks, may increase to 15 mg, then 20 mg maximum 7
• However, 20 mg carries higher risk of next-day impairment and driving hazards 7

Common Pitfalls to Avoid

1. Abrupt trazodone discontinuation: This significantly increases withdrawal symptom risk 3, 4. Always taper gradually.

2. Cross-tapering or adding Belsomra while still on trazodone: Research demonstrates this doubles the risk of oversedation and early discontinuation 6. The switching approach is superior to add-on therapy.

3. Starting Belsomra at 20 mg: Begin at 10 mg to assess tolerability 7. The 20 mg dose requires explicit counseling about next-day driving impairment 7.

4. Inadequate sleep opportunity: Belsomra requires a full 7-hour sleep window. Taking it with less time in bed increases next-day sedation risk 7.

5. Expecting immediate trazodone withdrawal: Symptoms may emerge 1-3 days after dose reduction due to short half-life 3. Plan the taper accordingly.

Monitoring During Transition

During trazodone taper, watch for:

• Anxiety, agitation, or mood changes
• Sleep disruption (expected temporarily)
• Physical symptoms: dizziness, nausea, headache
• If severe withdrawal occurs, slow the taper further 4, 5

After starting Belsomra, assess for:

• Next-day drowsiness or impaired alertness (especially first week) 7
• Complex sleep behaviors (sleepwalking, sleep-driving) - if these occur, discontinue immediately 7
• Sleep paralysis or hallucinations (dose-related) 7
• Worsening depression or suicidal ideation 7

Reevaluate at 7-10 days: If insomnia persists, consider other underlying causes rather than immediately increasing Belsomra dose 7.

Special Considerations

If patient has been on trazodone >1 year or has history of difficult medication discontinuation: Consider an even slower taper over 6-8 weeks, reducing by 25 mg every 1-2 weeks 8, 5. Some patients may require hyperbolic tapering (smaller decrements as dose decreases) 8, 9.

If patient is taking CYP3A inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice): Start Belsomra at 5 mg, not 10 mg 7.

If severe hepatic impairment: Belsomra is not recommended 7.